Patients receiving ATC gained an average of around 150 CD4 cells by week 24, but details of the average baseline CD4 cell count have not been released yet.
ATC was well tolerated, said Avexa, with no serious adverse events linked to the drug so far, and no adverse events reported at all by six of 50 participants in the study up to week 24. Two patients were withdrawn from the study due to unplanned pregnancies.
Avexa says it is now on course to launch phase III licensing studies of ATC, and recently bought the US marketing rights to the drug from Shire, its previous developer. Avexa now owns the worldwide marketing rights to Avexa, giving the small Melbourne-based company greater leverage in its likely search for a global marketing partner.
AVX Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
